Business

SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025

SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025 Hørsholm 26 February 2026 Company announcement #1 Pharma Equity Group A/S (the “Company”) hereby publishes the effects of a correction to the Company’s annual report for 2024 as well as the interim report for the first half of 2025. TABLE OF CONTENTS Background to the corrective informationManagement’s statementIndependent auditor’s reportCorrection to the consolidated financial statem

articlePharma Equity Group A/s Class AFebruary 26, 202648/company/pharma-equity-group-as-class-a/news/supplementary-information-corrective-information-to-the-annual-report-2024-and-the-interim-report-for-h1-2025
SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025

About this update from Pharma Equity Group A/s Class A

[{"type":"image","alt":"Pharma Equity Group A/S","displaySize":"","headline":null,"caption":"Pharma Equity Group A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PTz7GpCf_hKeFTaw0Xo7Fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c","width":300,"height":34}},"lazy":false},{"type":"text","content":"SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION)","length":50,"tagName":"p"},{"type":"text","content":"TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025","length":60,"tagName":"p"},{"type":"text","content":"Hørsholm 26 February 2026","length":25,"tagName":"p"},{"type":"text","content":"Company announcement #1","length":23,"tagName":"p"},{"type":"text","content":"Pharma Equity Group A/S (the “Company”) hereby publishes the effects of a correction to the Company’s annual report for 2024 as well as the interim report for the first half of 2025.","length":182,"tagName":"p"},{"type":"text","content":"TABLE OF CONTENTS","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Background to the corrective information","length":40,"tagName":"p"}]},{"val":[{"type":"text","content":"Management’s statement","length":22,"tagName":"p"}]},{"val":[{"type":"text","content":"Independent auditor’s report","length":28,"tagName":"p"}]},{"val":[{"type":"text","content":"Correction to the consolidated financial statements for 2024","length":60,"tagName":"p"}]}],"tagName":"ol","bulletedList":false,"length":150},{"type":"text","content":"a. Income statementb. Balance sheetc. Statement of changes in equityd. Cash flow statemente. Notes","length":102,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Correction to the parent company financial statements for 2024","length":62,"tagName":"p"}]}],"tagName":"ol","bulletedList":false,"length":62},{"type":"text","content":"a. Income statementb. Balance sheetc. Statement of changes in equityd. Cash flow statemente. Notes","length":102,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Correction to the interim financial statements for the first half of 2025","length":73,"tagName":"p"}]}],"tagName":"ol",...

More updates from Pharma Equity Group A/s Class A

ANNUAL REPORTThe Companyparent companyCash flow statementIndependent auditor’s reportPARENT COMPANYIncome statementDanish Business AuthorityAnnual ReportConsolidated Financial StatementCash and cash equivalents